Nothing Special   »   [go: up one dir, main page]

Radaelli et al., 2024 - Google Patents

Enhanced expression of the L1R gene of Vaccinia virus by the tPA signal sequence inserted in a Fowlpox-based recombinant vaccine

Radaelli et al., 2024

View HTML
Document ID
5552163824206563595
Author
Radaelli A
Zanotto C
Brambilla C
Adami T
De Giuli Morghen C
Publication year
Publication venue
Vaccines

External Links

Snippet

The use of Vaccinia virus (VACV) as a preventive vaccine against variola, the etiological agent of smallpox, led to the eradication of smallpox as a human disease. The L1 protein, a myristylated transmembrane protein present on the surface of mature virions, plays a …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Goatley et al. A pool of eight virally vectored African swine fever antigens protect pigs against fatal disease
Ramirez-Medina et al. Differential effect of the deletion of African swine fever virus virulence-associated genes in the induction of attenuation of the highly virulent Georgia strain
Focosi et al. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies
Loes et al. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice
Chandrasekar et al. Localized and systemic immune responses against SARS-CoV-2 following mucosal immunization
Aligholipour Farzani et al. Bovine herpesvirus type 4 (BoHV-4) vector delivering nucleocapsid protein of Crimean-congo hemorrhagic fever virus induces comparable protective immunity against lethal challenge in IFNα/β/γR−/− mice models
Zha et al. Development of a vaccine against SARS-CoV-2 based on the receptor-binding domain displayed on virus-like particles
Mamedov et al. Production and characterization of nucleocapsid and RBD cocktail antigens of SARS-CoV-2 in Nicotiana benthamiana plant as a vaccine candidate against COVID-19
Fiebig et al. Distribution of porcine cytomegalovirus in infected donor pigs and in baboon recipients of pig heart transplantation
Kalodimou et al. A soluble version of nipah virus glycoprotein G delivered by vaccinia virus MVA activates specific CD8 and CD4 T cells in mice
Seephetdee et al. Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2
Koltsova et al. Growth kinetics and protective efficacy of attenuated ASFV strain congo with deletion of the EP402 gene
Wang et al. Effects of adjuvants on the immunogenicity and efficacy of a Zika Virus envelope domain III subunit vaccine
Alharbi et al. Immunogenicity of high-dose MVA-based MERS vaccine candidate in mice and camels
Harahap-Carrillo et al. Immunogenic subviral particles displaying domain III of dengue 2 envelope protein vectored by measles virus
Wang et al. Evaluation of the immune response afforded by combined immunization with orf virus DNA and subunit vaccine in mice
Kibler et al. Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YMA30 strain of SARS-CoV-2
Grandi et al. Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
Li et al. CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
Sheehan et al. Dynamics of serum-neutralizing antibody responses in vaccinees through multiple doses of the BNT162b2 vaccine
Khlusevich et al. New p35 (H3L) epitope involved in vaccinia virus neutralization and its deimmunization
Temchura et al. Divergence of primary cognate B-and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particles
Saito et al. Vaccine candidates against arenavirus infections
Chiale et al. Modified alphavirus-vesiculovirus hybrid vaccine vectors for homologous prime-boost immunotherapy of chronic hepatitis B
Zeng et al. Characterization of a recombinant thermostable Newcastle disease virus (NDV) expressing glycoprotein gB of infectious laryngotracheitis virus (ILTV) protects chickens against ILTV challenge